Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 194

1.

Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse-Bordeaux DATAML Registry Study.

Bertoli S, Dumas PY, Bérard E, Largeaud L, Bidet A, Delabesse E, Tavitian S, Gadaud N, Leguay T, Leroy H, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Grande AC, Récher C, Pigneux A.

Cancers (Basel). 2020 Mar 25;12(4). pii: E773. doi: 10.3390/cancers12040773.

2.

MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia.

Montesinos P, Beckermann BM, Catalani O, Esteve J, Gamel K, Konopleva MY, Martinelli G, Monnet A, Papayannidis C, Park A, Récher C, Rodríguez-Veiga R, Röllig C, Vey N, Wei AH, Yoon SS, Fenaux P.

Future Oncol. 2020 Mar 13. doi: 10.2217/fon-2020-0044. [Epub ahead of print]

3.

Large granular lymphocytosis during quizartinib therapy.

Bertoli S, Rieu JB, Récher C, Vergez F.

Br J Haematol. 2020 Apr;189(1):7. doi: 10.1111/bjh.16373. Epub 2020 Mar 12. No abstract available.

PMID:
32162314
4.

More than ten percent of relapses occur after five years in AML patients with NPM1 mutation.

Bertoli S, Tavitian S, Bérard E, Mansat-De Mas V, Largeaud L, Gadaud N, Rieu JB, Vergez F, Luquet I, Huguet F, Sarry A, Delabesse E, Récher C.

Leuk Lymphoma. 2020 Feb 5:1-4. doi: 10.1080/10428194.2019.1706733. [Epub ahead of print] No abstract available.

PMID:
32022605
5.

Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France.

Tremblay G, Cariou C, Recher C, Dolph M, Brandt P, Blanc AS, Forsythe A.

Eur J Health Econ. 2020 Jan 22. doi: 10.1007/s10198-019-01149-9. [Epub ahead of print]

PMID:
31970530
6.

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, Deconinck E.

Blood Adv. 2019 Dec 23;3(24):4238-4251. doi: 10.1182/bloodadvances.2019000647.

7.

Multiple Severe Toxicities of L-Asparaginase and Their Innovative Management during Induction Therapy of Acute Lymphoblastic Leukemia in an Adult Patient.

Beziat G, Tavitian S, Picard M, Faguer S, Recher C, Huguet F.

Case Rep Hematol. 2019 Nov 20;2019:9086570. doi: 10.1155/2019/9086570. eCollection 2019.

8.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ.

N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688.

PMID:
31665578
9.

Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation.

Garciaz S, N'guyen Dasi L, Finetti P, Chevalier C, Vernerey J, Poplineau M, Platet N, Audebert S, Pophillat M, Camoin L, Bertucci F, Calmels B, Récher C, Birnbaum D, Chabannon C, Vey N, Duprez E.

Clin Epigenetics. 2019 Oct 12;11(1):141. doi: 10.1186/s13148-019-0738-6.

10.

Inflammation regulates long non-coding RNA-PTTG1-1:1 in myeloid leukemia.

Chateauvieux S, Gaigneaux A, Gérard D, Orsini M, Morceau F, Orlikova-Boyer B, Farge T, Récher C, Sarry JE, Dicato M, Diederich M.

Haematologica. 2019 Oct 3. pii: haematol.2019.217281. doi: 10.3324/haematol.2019.217281. [Epub ahead of print]

11.

Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors.

Largeaud L, Bertoli S, Bérard E, Dufrechou S, Prade N, Gadaud N, Tavitian S, Bories P, Luquet I, Sarry A, Mas V, Huguet F, Delabesse E, Récher C.

Leuk Lymphoma. 2020 Feb;61(2):473-476. doi: 10.1080/10428194.2019.1668937. Epub 2019 Sep 30. No abstract available.

PMID:
31566052
12.

Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients.

Berger E, Delpierre C, Despas F, Bertoli S, Bérard E, Bombarde O, Bories P, Sarry A, Laurent G, Récher C, Lamy S.

BMC Cancer. 2019 Sep 5;19(1):883. doi: 10.1186/s12885-019-6093-3.

13.

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L, Röllig C, Montesinos P, Martínez-Cuadrón D, Barragan E, García R, Botella C, Martínez P, Ravandi F, Kadia T, Kantarjian HM, Cortes J, Juliusson G, Lazarevic V, Höglund M, Lehmann S, Recher C, Pigneux A, Bertoli S, Dumas PY, Dombret H, Preudhomme C, Micol JB, Terré C, Ráčil Z, Novák J, Žák P, Wei AH, Tiong IS, Wall M, Estey E, Shaw C, Exeler R, Wagenführ L, Stölzel F, Thiede C, Stelljes M, Lenz G, Mikesch JH, Serve H, Ehninger G, Berdel WE, Kramer M, Krug U, Schliemann C.

J Clin Oncol. 2019 Oct 10;37(29):2632-2642. doi: 10.1200/JCO.19.00416. Epub 2019 Aug 20.

PMID:
31430225
14.

Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.

Hosseini M, Rezvani HR, Aroua N, Bosc C, Farge T, Saland E, Guyonnet-Dupérat V, Zaghdoudi S, Jarrou L, Larrue C, Sabatier M, Mouchel PL, Gotanègre M, Piechaczyk M, Bossis G, Récher C, Sarry JE.

Cancer Res. 2019 Oct 15;79(20):5191-5203. doi: 10.1158/0008-5472.CAN-19-0515. Epub 2019 Jul 29.

PMID:
31358527
15.

Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia.

Larrue C, Heydt Q, Saland E, Boutzen H, Kaoma T, Sarry JE, Joffre C, Récher C.

Oncogenesis. 2019 Jul 16;8(8):39. doi: 10.1038/s41389-019-0148-9.

16.

Outcome of patients aged 60-75 years with newly diagnosed secondary acute myeloid leukemia: A single-institution experience.

Bertoli S, Tavitian S, Bories P, Luquet I, Delabesse E, Comont T, Sarry A, Huguet F, Bérard E, Récher C.

Cancer Med. 2019 Jul;8(8):3846-3854. doi: 10.1002/cam4.2020. Epub 2019 Jun 7.

17.

Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.

Largeaud L, Bérard E, Bertoli S, Dufrechou S, Prade N, Gadaud N, Tavitian S, Bories P, Luquet I, Sarry A, De Mas V, Huguet F, Delabesse E, Récher C.

Leuk Res. 2019 Jun;81:82-87. doi: 10.1016/j.leukres.2019.04.010. Epub 2019 Apr 27.

PMID:
31055247
18.

Hydroxyurea prior to intensive chemotherapy in AML with moderate leukocytosis.

Bertoli S, Tavitian S, Picard M, Huguet F, Vergez F, Delabesse E, Sarry A, Bérard E, Récher C.

Leuk Res. 2018 Dec;75:7-10. doi: 10.1016/j.leukres.2018.10.015. Epub 2018 Oct 31. No abstract available.

PMID:
30419550
19.

Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.

Bertoli S, Paubelle E, Bérard E, Saland E, Thomas X, Tavitian S, Larcher MV, Vergez F, Delabesse E, Sarry A, Huguet F, Larrue C, Bosc C, Farge T, Sarry JE, Michallet M, Récher C.

Eur J Haematol. 2019 Feb;102(2):131-142. doi: 10.1111/ejh.13183. Epub 2018 Nov 28.

PMID:
30325535
20.

Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

Pigneux A, Béné MC, Salmi LR, Dumas PY, Delaunay J, Bonmati C, Guièze R, Luquet I, Cornillet-Lefebvre P, Delabesse E, Ianotto JC, Ojeda-Uribe M, Hunault M, Banos A, Fornecker LM, Bernard M, Jourdan E, Vey N, Zerazhi H, Hishri Y, Mineur A, Asselineau J, Delepine R, Cahn JY, Ifrah N, Récher C; French Innovative Leukemia Organization.

J Clin Oncol. 2018 Sep 27:JCO2018787366. doi: 10.1200/JCO.2018.78.7366. [Epub ahead of print]

PMID:
30260758
21.

FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.

Perry M, Bertoli S, Rocher C, Hayette S, Ducastelle S, Barraco F, Labussière-Wallet H, Salles G, Recher C, Thomas X, Paubelle E.

Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):e545-e550. doi: 10.1016/j.clml.2018.06.006. Epub 2018 Jun 13.

PMID:
30082225
22.

Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Adès L, Thomas X, Bresler AG, Raffoux E, Spertini O, Vey N, Marchand T, Récher C, Pigneux A, Girault S, Deconinck E, Gardin C, Tournilhac O, Lambert JF, Chevallier P, de Botton S, Lejeune J, Dombret H, Chevret S, Fenaux P.

Haematologica. 2018 Dec;103(12):2033-2039. doi: 10.3324/haematol.2018.198614. Epub 2018 Jul 19.

23.

Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia: results of a national survey.

Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, Fornecker L, Moreau S, Récher C, Nebout A.

Haematologica. 2018 Dec;103(12):2040-2048. doi: 10.3324/haematol.2018.192468. Epub 2018 Jul 13.

24.

Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.

Bertoli S, Tavitian S, Berard E, Gadaud N, Luquet I, Huynh A, Sarry A, Huguet F, Récher C.

Leuk Lymphoma. 2019 Jan;60(1):238-241. doi: 10.1080/10428194.2018.1464156. Epub 2018 Jun 12. No abstract available.

PMID:
29893611
25.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

26.

NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Prata PH, Bally C, Prebet T, Recher C, Venton G, Thomas X, Raffoux E, Pigneux A, Cluzeau T, Desoutter J, Gay J, Preudhomme C, Fenaux P, Adès L.

Haematologica. 2018 Oct;103(10):e455-e457. doi: 10.3324/haematol.2018.189886. Epub 2018 May 10. No abstract available.

27.

Risk of Hematologic Malignancies After Radioactive Iodine Treatment of Thyroid Cancer: An Unjustified Warning.

Hindié E, Récher C, Zerdoud S, Leenhardt L, Avram AM.

J Clin Oncol. 2018 Jun 20;36(18):1881-1882. doi: 10.1200/JCO.2018.78.1096. Epub 2018 May 3. No abstract available.

PMID:
29723097
28.

DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.

Grgurevic S, Montilla-Perez P, Bradbury A, Gilhodes J, Queille S, Pelofy S, Bancaud A, Filleron T, Ysebaert L, Récher C, Laurent G, Fournié JJ, Cazaux C, Quillet-Mary A, Hoffmann JS.

Haematologica. 2018 Jun;103(6):1038-1046. doi: 10.3324/haematol.2017.174243. Epub 2018 Mar 22.

29.

Dexamethasone in hyperleukocytic acute myeloid leukemia.

Bertoli S, Picard M, Bérard E, Griessinger E, Larrue C, Mouchel PL, Vergez F, Tavitian S, Yon E, Ruiz J, Delabesse E, Luquet I, Linares LK, Saland E, Carroll M, Danet-Desnoyers G, Sarry A, Huguet F, Sarry JE, Récher C.

Haematologica. 2018 Jun;103(6):988-998. doi: 10.3324/haematol.2017.184267. Epub 2018 Mar 8.

30.

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.

Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H.

BMC Cancer. 2017 Dec 14;17(1):852. doi: 10.1186/s12885-017-3803-6.

31.

Dendrogenin A drives LXR to trigger lethal autophagy in cancers.

Segala G, David M, de Medina P, Poirot MC, Serhan N, Vergez F, Mougel A, Saland E, Carayon K, Leignadier J, Caron N, Voisin M, Cherier J, Ligat L, Lopez F, Noguer E, Rives A, Payré B, Saati TA, Lamaziere A, Despres G, Lobaccaro JM, Baron S, Demur C, de Toni F, Larrue C, Boutzen H, Thomas F, Sarry JE, Tosolini M, Picard D, Record M, Récher C, Poirot M, Silvente-Poirot S.

Nat Commun. 2017 Dec 4;8(1):1903. doi: 10.1038/s41467-017-01948-9.

32.

Improved outcome for AML patients over the years 2000-2014.

Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, Delabesse E, Sarry A, Laurent G, Attal M, Huguet F, Bérard E, Récher C.

Blood Cancer J. 2017 Nov 29;7(12):635. doi: 10.1038/s41408-017-0011-1.

33.

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia.

Dumas PY, Bertoli S, Bérard E, Médiavilla C, Yon E, Tavitian S, Leguay T, Huguet F, Forcade E, Milpied N, Sarry A, Sauvezie M, Bories P, Pigneux A, Récher C.

Oncotarget. 2017 Mar 7;8(45):79126-79136. doi: 10.18632/oncotarget.15988. eCollection 2017 Oct 3.

34.

Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance.

David L, Manenti S, Récher C, Hoffmann JS, Didier C.

Mol Cell Oncol. 2017 Sep 18;4(5):e1289293. doi: 10.1080/23723556.2017.1289293. eCollection 2017.

35.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D; ANRS-CO16 LYMPHOVIR Cohort.

AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.

PMID:
28926410
36.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Hospital MA, Jacquel A, Mazed F, Saland E, Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, Gautier EF, Salnot V, Le Gall M, Decroocq J, Poulain L, Jacque N, Fontenay M, Kosmider O, Récher C, Auberger P, Mayeux P, Bouscary D, Sarry JE, Tamburini J.

Leukemia. 2018 Mar;32(3):597-605. doi: 10.1038/leu.2017.284. Epub 2017 Sep 15.

PMID:
28914261
37.

Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy.

Comont T, Tavitian S, Bardiaux L, Fort M, Debiol B, Morère D, Bérard E, Delabesse E, Luquet I, Martinez S, Huguet F, Récher C, Bertoli S.

Leuk Res. 2017 Oct;61:62-67. doi: 10.1016/j.leukres.2017.08.015. Epub 2017 Aug 30.

PMID:
28910610
38.

Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S, Demur C, Delabesse E, Recher C, Touriol C, Martelli MP, Falini B, Brousset P, Bousquet M.

Haematologica. 2017 Oct;102(10):1718-1726. doi: 10.3324/haematol.2017.171645. Epub 2017 Jul 4.

39.

Bendamustine for relapsed blastic plasmacytoid dendritic cell leukaemia.

Bétrian S, Guenounou S, Luquet I, Demur C, Huynh A, Ysebaert L, Recher C, Huguet F.

Hematol Oncol. 2017 Jun;35(2):252-255. doi: 10.1002/hon.2252. Epub 2015 Oct 8.

PMID:
28620927
40.

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial.

Hunault-Berger M, Maillard N, Himberlin C, Recher C, Schmidt-Tanguy A, Choufi B, Bonmati C, Carré M, Couturier MA, Daguindau E, Marolleau JP, Orsini-Piocelle F, Delaunay J, Tavernier E, Lissandre S, Ojeda-Uribe M, Sanhes L, Sutton L, Banos A, Fornecker LM, Bernard M, Bouscary D, Saad A, Puyade M, Rouillé V, Luquet I, Béné MC, Hamel JF, Dreyfus F, Ifrah N, Pigneux A.

Blood Cancer J. 2017 Jun 2;7(6):e568. doi: 10.1038/bcj.2017.50. No abstract available.

41.

Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism.

Farge T, Saland E, de Toni F, Aroua N, Hosseini M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, Scotland S, Larrue C, Boutzen H, Féliu V, Nicolau-Travers ML, Cassant-Sourdy S, Broin N, David M, Serhan N, Sarry A, Tavitian S, Kaoma T, Vallar L, Iacovoni J, Linares LK, Montersino C, Castellano R, Griessinger E, Collette Y, Duchamp O, Barreira Y, Hirsch P, Palama T, Gales L, Delhommeau F, Garmy-Susini BH, Portais JC, Vergez F, Selak M, Danet-Desnoyers G, Carroll M, Récher C, Sarry JE.

Cancer Discov. 2017 Jul;7(7):716-735. doi: 10.1158/2159-8290.CD-16-0441. Epub 2017 Apr 17.

42.

High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells.

Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M, Palama TL, Chesnais V, Birsen R, Vergez F, Farge T, Chenevier-Gobeaux C, Fraisse M, Bouillaud F, Debeissat C, Herault O, Récher C, Lacombe C, Fontenay M, Mayeux P, Maciel TT, Portais JC, Sarry JE, Tamburini J, Bouscary D, Chapuis N.

Leukemia. 2017 Nov;31(11):2326-2335. doi: 10.1038/leu.2017.81. Epub 2017 Mar 10.

PMID:
28280275
43.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

J Clin Oncol. 2017 Apr 10;35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

PMID:
28221862
44.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

Pigneux A, Béné MC, Guardiola P, Recher C, Hamel JF, Sauvezie M, Harousseau JL, Tournilhac O, Witz F, Berthou C, Escoffre-Barbe M, Guyotat D, Fegueux N, Himberlin C, Hunault M, Delain M, Lioure B, Jourdan E, Bauduer F, Dreyfus F, Cahn JY, Sotto JJ, Ifrah N.

J Clin Oncol. 2017 Feb;35(4):387-393. doi: 10.1200/JCO.2016.67.6213. Epub 2016 Oct 24.

PMID:
28129526
45.

Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia.

Cahu X, Carré M, Recher C, Pigneux A, Hunault-Berger M, Vey N, Chevallier P, Delaunay J, Gyan E, Lioure B, Bonmati C, Himberlin C, Hicheri Y, Guillerm G, Didier B, Larosa F, Ojeda-Uribe M, Bernard M, Bene MC, Ifrah N, Cahn JY.

Eur J Haematol. 2017 May;98(5):443-449. doi: 10.1111/ejh.12850. Epub 2017 Mar 1.

PMID:
28122150
46.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

47.

Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.

Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C.

Leuk Lymphoma. 2017 Aug;58(8):1880-1886. doi: 10.1080/10428194.2016.1263843. Epub 2016 Dec 2.

PMID:
27911138
48.

Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response.

Guenounou S, Borel C, Bérard E, Yon E, Fort M, Mengelle C, Bertoli S, Sarry A, Tavitian S, Huguet F, Attal M, Récher C, Huynh A.

Medicine (Baltimore). 2016 Nov;95(48):e5356.

49.

Bcl-2 protein family expression pattern determines synergistic pro-apoptotic effects of BH3 mimetics with hemisynthetic cardiac glycoside UNBS1450 in acute myeloid leukemia.

Cerella C, Gaigneaux A, Mazumder A, Lee JY, Saland E, Radogna F, Farge T, Vergez F, Récher C, Sarry JE, Kim KW, Shin HY, Dicato M, Diederich M.

Leukemia. 2017 Mar;31(3):755-759. doi: 10.1038/leu.2016.341. Epub 2016 Nov 22. No abstract available.

50.

Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies.

Bertoli S, Sterin A, Tavitian S, Oberic L, Ysebaert L, Bouabdallah R, Vergez F, Sarry A, Bérard E, Huguet F, Laurent G, Prébet T, Vey N, Récher C.

Oncotarget. 2016 Dec 27;7(52):85937-85947. doi: 10.18632/oncotarget.13262.

Supplemental Content

Loading ...
Support Center